Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

570 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MEK inhibitor for gastric cancer with MEK1 gene mutations.
Sogabe S, Togashi Y, Kato H, Kogita A, Mizukami T, Sakamoto Y, Banno E, Terashima M, Hayashi H, de Velasco MA, Sakai K, Fujita Y, Tomida S, Yasuda T, Takeyama Y, Okuno K, Nishio K. Sogabe S, et al. Among authors: mizukami t. Mol Cancer Ther. 2014 Dec;13(12):3098-106. doi: 10.1158/1535-7163.MCT-14-0429. Epub 2014 Sep 24. Mol Cancer Ther. 2014. PMID: 25253779
An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer.
Togashi Y, Mizuuchi H, Kobayashi Y, Hayashi H, Terashima M, Sakai K, Banno E, Mizukami T, Nakamura Y, de Velasco MA, Fujita Y, Tomida S, Mitsudomi T, Nishio K. Togashi Y, et al. Among authors: mizukami t. Ann Oncol. 2015 Aug;26(8):1800-1. doi: 10.1093/annonc/mdv240. Epub 2015 May 22. Ann Oncol. 2015. PMID: 26002608 Free article. No abstract available.
Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies.
Mizukami T, Togashi Y, Naruki S, Banno E, Terashima M, de Velasco MA, Sakai K, Yoneshige A, Hayashi H, Fujita Y, Tomida S, Nakajima TE, Fujino T, Boku N, Ito A, Nakagawa K, Nishio K. Mizukami T, et al. Mol Carcinog. 2017 Jan;56(1):106-117. doi: 10.1002/mc.22476. Epub 2016 Feb 24. Mol Carcinog. 2017. PMID: 26916220
Identification of a FGFR3-TACC3 fusion in esophageal cancer.
Mizukami T, Sakai K, Naruki S, Taniyama T, Horie Y, Izawa N, Tsuda T, Fujino T, Boku N, Yasuda H, Fukunaga T, Nakajima TE, Nishio K. Mizukami T, et al. Ann Oncol. 2017 Feb 1;28(2):437-438. doi: 10.1093/annonc/mdw550. Ann Oncol. 2017. PMID: 27771611 Free article. No abstract available.
Association of ERBB2 Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2-Positive Esophagogastric and Gastric Cancer.
Hino K, Nishina T, Kajiwara T, Bando H, Nakamura M, Kadowaki S, Minashi K, Yuki S, Ohta T, Hara H, Mizukami T, Moriwaki T, Ohtsubo K, Komoda M, Mitani S, Nagashima F, Kato K, Yamada T, Hasegawa H, Yamazaki K, Yoshino T, Hyodo I. Hino K, et al. Among authors: mizukami t. JCO Precis Oncol. 2022 Aug;6:e2200135. doi: 10.1200/PO.22.00135. JCO Precis Oncol. 2022. PMID: 35952320 Free PMC article.
570 results